Kisspeptin-14: natural brain signal for reproductive hormone release
A short protein fragment made naturally in the body that tells the brain to release reproductive hormones; used only as a lab research tool.
A researcher, an agent, or an algorithm wrote down the sequence and picked a target to hit.
An AI model like OpenFold3 or AlphaFold built a 3D structure and scored how well it fits the binding site.
A second contributor repeated the computation on their own hardware and the scores matched.
A chemistry service or a researcher ordered the sequence, it was manufactured, and mass spectrometry confirmed the right molecule was produced.
A binding or activity measurement confirmed that it actually does what the computer predicted — or didn't.
What this is
Kisspeptin-14 is a 14-residue peptide fragment naturally produced in the body from the KiSS-1 gene product. The KiSS-1 gene encodes a 145-amino-acid precursor protein that is proteolytically cleaved into several shorter bioactive fragments — kisspeptin-54, kisspeptin-14, kisspeptin-13, and kisspeptin-10 — all of which share the same C-terminal core sequence responsible for receptor activation (Gottsch and colleagues 2009; Tena-Sempere 2006). Kisspeptin-14 is one of the shorter members of this family, studied as a research tool for understanding how the brain controls reproductive hormone secretion. The stored sequence DLPNYNWNSFGLRF represents the 14-residue C-terminal fragment; all biologically active kisspeptin fragments share this C-terminal RF-containing region required for binding to the kisspeptin receptor.
History
The story of kisspeptin-14 begins with the discovery of the KiSS-1 gene in 1996, initially identified as a metastasis suppressor in melanoma cells — and named in a nod to Hershey, Pennsylvania (home of Hershey's Kisses), where it was found (Tena-Sempere 2006). The peptide products of KiSS-1 were identified in 2001 as the natural ligands of GPR54, an orphan G protein-coupled receptor (Tena-Sempere 2006). The reproductive biology connection crystallized in late 2003, when two independent groups reported that loss-of-function mutations in GPR54 caused hypogonadotropic hypogonadism and absent puberty onset, establishing kisspeptin signaling as essential for reproductive axis function (Tena-Sempere 2006). The systematic naming of kisspeptin fragments — including kisspeptin-14 — was consolidated by Gottsch and colleagues (2009) in a historical review that proposed standardized nomenclature for the KISS1 peptide family. Evolutionary studies in fish showed that kisspeptin systems are broadly conserved across vertebrates, with paralogous kiss1 and kiss2 genes in some species (Akazome and colleagues 2010), and kisspeptin-14 appears in sequence alignment tables as a recognized bioactive fragment across mammalian species.
What it does
Kisspeptin-14, like other kisspeptin fragments, binds to and activates the kisspeptin receptor (KISS1R, also called GPR54) — a class A G protein-coupled receptor expressed on GnRH neurons in the hypothalamus. This triggers pulsatile release of gonadotropin-releasing hormone (GnRH), which in turn drives secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary, ultimately controlling testosterone and estrogen production from the gonads (Xie and colleagues 2022; Kirby and colleagues 2010). The hypothalamic neurons most relevant to this signaling are the KNDy neurons in the arcuate nucleus, which co-express kisspeptin, neurokinin B, and dynorphin and generate the pulsatile GnRH output pattern that governs reproductive cyclicity (Xie and colleagues 2022). Kisspeptin signaling also integrates metabolic and circadian information, linking energy balance to reproductive readiness (Tena-Sempere 2006). Beyond reproduction, kisspeptin family members have been implicated in glucose homeostasis regulation, with conflicting reports across animal models and associations between circulating kisspeptin levels and insulin sensitivity in human studies (Izzi-Engbeaya and colleagues 2019). The role of kisspeptin in sexual behavior has also been examined, with rodent studies revealing that kisspeptin neurons integrate olfactory cues to influence mate preference and lordosis (Hellier and colleagues 2019).
Evidence
- Human: Clinical research has focused primarily on kisspeptin-54 and kisspeptin-10 rather than kisspeptin-14 specifically. Kisspeptin-54 potently stimulates gonadotropin release in healthy women across the menstrual cycle, with the strongest response during the preovulatory phase (Dhillo and colleagues 2007). Subcutaneous kisspeptin-54 acutely stimulates LH secretion in women with hypothalamic amenorrhea, though chronic administration produces tachyphylaxis (Jayasena and colleagues 2009). Kisspeptin-10 stimulates reproductive hormone release with sexual dimorphism in humans — effects on LH and FSH differ between men and women (Jayasena and colleagues 2011). Kisspeptin-14 has been employed in research contexts as part of the kisspeptin fragment family, but human trials have used longer forms.
- Animal: Kisspeptin biology is extensively characterized in rodent, ovine, and other mammalian models, where KNDy neuron circuits and kisspeptin's role in GnRH pulse generation are well established (Okamura and colleagues 2013; Rønnekleiv and colleagues 2013).
- In vitro / mechanistic: KISS1R pharmacology is well characterized. The receptor nomenclature, distribution, and signaling properties were systematically reviewed by Kirby and colleagues (2010) for the International Union of Basic and Clinical Pharmacology.
Known effects
- GnRH and gonadotropin stimulation — Well-established mechanistically; demonstrated in humans for kisspeptin-54 and kisspeptin-10 (Dhillo and colleagues 2007; Jayasena and colleagues 2011)
- Reproductive axis control — Strong mechanistic and animal evidence; clinical evidence accrued for longer kisspeptin forms (Xie and colleagues 2022; Okamura and colleagues 2013)
- Tachyphylaxis on continuous exposure — Documented for kisspeptin-54; sustained infusion causes receptor desensitization (Jayasena and colleagues 2009)
- Sexual behavior modulation — Preclinical evidence in rodents; human brain-imaging studies conducted with longer kisspeptin forms (Hellier and colleagues 2019)
- Glucose homeostasis involvement — Mechanistic and association data; direction of effect varies across models (Izzi-Engbeaya and colleagues 2019)
Safety signals
Published clinical safety information derives from human studies with kisspeptin-54 and kisspeptin-10, not kisspeptin-14 specifically. In trials examining reproductive hormone stimulation and hypothalamic amenorrhea, kisspeptin-54 was reported to be well tolerated at the doses studied; injection site reactions were the most common adverse finding (Jayasena and colleagues 2009). The tachyphylaxis phenomenon — receptor desensitization with continuous exposure — has functional implications for how kisspeptin can be delivered, limiting sustained use protocols (Jayasena and colleagues 2009). Kisspeptin's role as a KiSS-1 gene product intersects with the gene's original characterization as a metastasis suppressor; however, evidence for oncological risk from exogenous kisspeptin administration in therapeutic contexts has not been established in the published literature reviewed here.
Regulatory status
- US: Kisspeptin peptides are not FDA-approved for any indication. No kisspeptin product holds marketing authorization in the United States.
- EU/UK: Similarly investigational. The UK has hosted substantial human clinical research on kisspeptin-54 and kisspeptin-10, but no marketing authorization has been granted by the MHRA or EMA.
- WADA: Kisspeptin falls under the S2 (peptide hormones, growth factors, and related substances) prohibited class at all times due to its LH/FSH-stimulating activity; athletes in regulated competition must avoid all kisspeptin forms.
Mechanism
Kisspeptin-14 activates KISS1R (GPR54), a class A Gαq-coupled receptor, via the C-terminal RF-containing sequence shared by all bioactive kisspeptin fragments (Kirby and colleagues 2010). Receptor activation stimulates phospholipase C, elevating intracellular calcium and diacylglycerol, which depolarizes GnRH neurons and triggers GnRH pulse release into the portal circulation (Rønnekleiv and colleagues 2013). The downstream pituitary response — LH and FSH secretion — drives gonadal steroidogenesis, completing the hypothalamic-pituitary-gonadal (HPG) axis cascade (Xie and colleagues 2022). KNDy neurons in the hypothalamic arcuate nucleus are the principal source of kisspeptin input to GnRH neurons; they co-express neurokinin B (which drives kisspeptin release) and dynorphin (which terminates pulses), creating the auto-regulatory oscillator underlying GnRH pulsatility (Xie and colleagues 2022). The kisspeptin system also receives metabolic, stress, and photoperiodic signals, integrating systemic state into reproductive axis output (Tena-Sempere 2006; Tsutsui and colleagues 2010).
Open questions
- No clinical data exist specifically for kisspeptin-14 in humans; its receptor binding and pharmacokinetics relative to the longer forms remain to be directly compared in human studies.
- The relative potency of kisspeptin-14 versus kisspeptin-10 and kisspeptin-54 at KISS1R under physiological conditions is not fully resolved.
- Whether kisspeptin-14 has distinct metabolic (glucose homeostasis) effects compared to other fragments, given conflicting reports across kisspeptin isoforms and species (Izzi-Engbeaya and colleagues 2019), remains an open question.
- The net effect of the KiSS-1 gene's dual role — metastasis suppressor in some cancer contexts, reproductive regulator in normal physiology — on cancer risk with exogenous kisspeptin administration has not been established.
Related peptides
- Kisspeptin-10 (Human) — The 10-residue C-terminal fragment, the shortest biologically active kisspeptin form; shares the C-terminal core with Kp-14. See Kisspeptin-10 (Human).
- Kisspeptin-54 — The 54-residue processed form of the KiSS-1 precursor; the isoform most studied in human IVF trigger and hypothalamic amenorrhea trials. See Kisspeptin-54/Kp54.
- Kisspeptin-13 (Human) — The 13-residue fragment, one position shorter than Kp-14 at the N-terminus, sharing the same C-terminal receptor-binding core. See Kisspeptin-13 (Human).
Research directions for this peptide, selected from the current sources — hypotheses you can explore and model. None of it is proven yet; tap any one to see the full thinking.
Is there a spot on this hormone fragment where chemists could attach a slow-release tag without breaking how it works?
Kisspeptin is a natural hormone that triggers the reproductive axis, but it vanishes from the blood in minutes, making it nearly useless as a drug. If this attachment site holds up, it could lead to a once-daily injection for people with low sex hormone levels caused by a signaling failure in the brain, a condition that causes infertility and bone loss.
Could a small structural difference make this hormone fragment last long enough to be practically useful as a medicine?
Most peptide drugs are destroyed in the blood within minutes. If the extra three amino acids on kisspeptin-14 slow that breakdown, it could sit in a sweet spot: lasting longer than the shortest form without triggering the receptor burnout seen with the longest form, making it a more practical candidate for treating hormone deficiency.
Could this peptide help the pancreas release insulin without also disrupting the reproductive hormone system?
Treatments that stimulate insulin release often come with hormonal side effects. If kisspeptin-14 acts directly on pancreatic cells at doses too small to activate the reproductive axis, it could offer a cleaner path to blood sugar control, potentially relevant for type 2 diabetes, and would be particularly valuable for patients where hormonal disruption is a concern.
Could this shorter form of kisspeptin stay effective with repeated dosing, while the longer forms lose their effect?
A common problem with kisspeptin therapy is that receptors stop responding after repeated exposure, a phenomenon called tachyphylaxis. If kisspeptin-14 clears quickly enough between doses to let receptors recover, it could remain effective over weeks of pulsatile treatment for conditions like hypothalamic amenorrhea or unexplained infertility where current protocols plateau.
Could a fragment of this naturally occurring peptide block cancer cells from spreading without messing with hormone levels?
Kisspeptin was originally discovered as a gene that suppresses cancer spread in melanoma and breast cancer. If kisspeptin-14 can block tumor cell invasion at doses that stay below the threshold for activating the reproductive axis, it would be the first version to separate those two effects, potentially becoming a cancer treatment candidate derived from a molecule the body already produces.
▸full evidence table2 metrics
| metric | value | tool |
|---|---|---|
| ipTM | 0.9059688448905945 | boltz-2 |
| ranking score | 0.7395108342170715 | boltz-2 |
▸3-letter notation
▸recipeboltz-2 2.2.1
| parameter | value |
|---|---|
| model | boltz-2 2.2.1 |
| weights | — |
| hardware | vast_v100_32gb |
| mlx version | — |
| python | — |
| random seed | 1 |
| msa strategy | colabfold_local |
| runtime | — |
| predicted by | — |
| predicted at | 2026-05-22 |
▸citationbibtex
@peptide{pep10524,
sequence = {DLPNYNWNSFGLRF},
target = {kiss1r},
author = {peptidemodel},
year = {2026},
status = {synthesized}
}